Table 4.
Stratified analyses for the association between subclinical hyperthyroidism and Heart Failure (HF) Events
| HF Events
|
||||||
|---|---|---|---|---|---|---|
| Euthyroidism | Subclinical Hyperthyroidism | HR (95% CI) age/gender-adjusted | HR (95% CI) multivariate model* | |||
| Events | Participants | Events | Participants | |||
| Total population | 1762 | 22,674 | 57 | 648 | 1.46 (0.94, 2.27) | 1.51 (0.93, 2.44) |
| Gender† | ||||||
| Men | 977 | 10,793 | 20 | 219 | 1.22 (0.77, 1.94) | 1.21 (0.77, 1.89) |
| Women | 785 | 11,881 | 37 | 429 | 1.72 (1.02, 2.91) | 1.56 (0.97, 2.50) |
| P for interaction | 0.33 | 0.45 | ||||
| Age‡ (years) | ||||||
| 18–49§ | 15 | 2756 | 0 | 71 | 1.95 (0.10, 39.59) | 2.61 (0.14, 49.09) |
| 50–64 | 128 | 5798 | 4 | 151 | 1.79 (0.26, 12.34) | 1.63 (0.26, 10.02) |
| 65–79 | 1370 | 12,666 | 37 | 375 | 1.20 (0.82, 1.77) | 1.20 (0.81, 1.76) |
| ≥ 80 | 249 | 1454 | 16 | 51 | 2.34 (1.27, 4.31) | 2.40 (1.19, 4.85) |
| P for trend | 0.98 | 0.91 | ||||
| Race | ||||||
| Caucasian | 1573 | 21,541 | 52 | 615 | 1.49 (0.95, 2.35) | 1.50 (0.95, 2.35) |
| Black | 189 | 1133 | 5 | 33 | 1.07 (0.46, 2.51) | 1.07 (0.45, 2.53) |
| P for interaction | 0.50 | 0.50 | ||||
| TSH (mIU/L) | ||||||
| 0.45–4.49 | 1762 | 22,674 | 1 (ref) | 1 (ref) | ||
| 0.10–0.44 | 41 | 494 | 1.31 (0.88, 1.95) | 1.31 (0.88, 1.94) | ||
| <0.10 | 16 | 154 | 1.94 (1.01, 3.72) | 1.92 (0.99, 3.71) | ||
| P for trend | 0.047 | 0.054 | ||||
| Preexisting CVD|| | ||||||
| None | 1091 | 18,448 | 33 | 532 | 1.50 (0.92, 2.44) | 1.37 (0.92, 2.03) |
| Yes | 669 | 4214 | 24 | 116 | 1.46 (0.84, 2.55) | 1.44 (0.83, 2.50) |
| P for interaction | 0.94 | 0.89 | ||||
| Preexisting HF# | ||||||
| None | 1205 | 10,247 | 38 | 273 | 1.49 (0.87, 2.56) | 1.47 (0.84, 2.59) |
| Yes | 132 | 440 | 7 | 15 | 1.64 (0.56, 4.86) | 1.48 (0.45, 4.91) |
| P for interaction | 0.88 | 0.99 | ||||
Abbreviations: CI, Confidence Interval; CVD, Cardiovascular Disease; HF, Heart Failure; HR, Hazard Ratio; NA, data not applicable; TSH, Thyroid-Stimulating Hormone.
Adjusted for age, gender, systolic blood pressure, current and former smoking, total cholesterol and prevalent diabetes at baseline.
These HRs were not adjusted for gender.
These HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.
Bari was excluded from this stratum because of no participants in subclinical hyperthyroidism group.
Data on previous CVD were not available for 10 participants in EPIC and for 2 participants in Leiden-study
No data available in EPIC (only preexisting overall CVD assessed), 1 missing value in Leiden. No participants in PROSPER had preexisting HF and all participants had HF at baseline in Bari study (inclusion criteria)